The Who, What, Where, When and Sometimes, Why.

Emerging Areas in Research on Estimating Risk and Risk Reduction

Breast cancer risk assessment and risk reduction are active areas of research.

Researchers are looking at new and better ways of knowing which women and men are at high risk.

Other researchers are studying ways to lower risk (such as new risk-reducing drugs) in people at high risk of breast cancer.

Read our blog, “It Looks Promising”: Dr. Kornelia Polyak is Uncovering New Possibilities in Breast Cancer Prevention.

Risk assessment models

As research in risk assessment grows, current tools like the Breast Cancer Risk Assessment Tool (the Gail Model) and IBIS (the Tyrer-Cuzick model) will be better able to predict breast cancer risk in large groups of women.

New risk assessment models may incorporate imaging and genetic information to estimate breast cancer risk. They may use artificial intelligence (AI) to improve risk estimates [408].

Artificial intelligence (AI), mammograms and risk assessment

Some models use AI to look at mammography images and estimate breast cancer risk [409-410]. These AI models are trained on a large number of screening mammogram images to identify which images are most likely to show signs of breast cancer over time.

AI imaging-based models estimate a woman’s breast cancer risk based on her mammogram. Women found to be at higher-than-average risk based on an AI imaging-based risk model may have special breast cancer screening recommendations [183].

At this time, mammography that includes an AI-based risk model is not widely available and is not covered by insurance.

Learn about breast cancer screening for women at higher risk.

Risk-reducing drugs

Some drugs used to treat breast cancer are under study in the risk reduction setting for women at higher risk.

New risk-reducing drugs are also being developed.

Learn about tamoxifen and raloxifene (FDA-approved drugs for lowering the risk of breast cancer).

Aromatase inhibitors

Aromatase inhibitors are hormone therapy drugs used to treat estrogen receptor-positive breast cancer in postmenopausal women.

Exemestane (Aromasin) and anastrozole (Arimidex) are aromatase inhibitor drugs. Findings from randomized controlled trials have shown exemestane and anastrozole may reduce the risk of breast cancer by about half for postmenopausal women at high risk [252-253].

The American Society for Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN) and the U.S. Preventive Services Task Force list exemestane and anastrozole as risk-reducing drug options for postmenopausal women who do not have breast cancer, but are at high risk of breast cancer.

However, exemestane and anastrozole are not FDA-approved for use in the risk reduction setting. They are only FDA-approved for use in breast cancer treatment.

Letrozole (Femara)

The aromatase inhibitor drug letrozole (Femara) is under study to see whether it lowers breast cancer risk in postmenopausal women at high risk.

Learn about aromatase inhibitors and breast cancer treatment.

Learn more about the side effects of aromatase inhibitors.

Lasofoxifene

Lasofoxifene is an osteoporosis drug similar to tamoxifen and raloxifene.

Early findings suggest lasofoxifene may reduce the risk of breast cancer in women at increased risk of osteoporosis [411-413]. More data are needed to confirm these findings.

Clinical trials of risk-reducing drugs

If you’re at higher risk of breast cancer and considering joining a risk-reducing drug clinical trial, discuss the potential risks and benefits with your health care provider.

Susan G. Komen® Patient Care Center

If you or a loved one needs information or resources about clinical trials, the Patient Care Center can help. Contact the Komen Breast Care Helpline at 1-877-465-6636 or email clinicaltrialinfo@komen.org.

Se habla español.

BreastCancerTrials.org in collaboration with Komen offers a custom matching service to help find breast cancer risk reduction clinical trials.

Learn more about clinical trials.

Using breast cells to assess risk

Using breast cells to assess breast cancer risk is under study. Cells are removed from the breast and a pathologist looks at the cells under a microscope. Abnormal (atypical) cells may be linked to an increased risk of breast cancer, but these tests have not been shown to be effective for breast cancer risk assessment [414].

These include:

  • Ductal lavage uses a small tube to flush out fluid from the nipple. This fluid contains breast cells. This procedure causes some discomfort.
  • Nipple aspiration (nipple aspirate fluid cytology), such as the HALO test, uses a breast pump, and sometimes massage, to remove fluid from the nipple.
  • Random periareolar fine needle aspiration (RPFNA) uses a thin needle to remove cells from about 10 areas near the areola. This procedure is more invasive and causes more discomfort than ductal lavage or nipple aspiration.

Ductal lavage, nipple aspiration and RPFNA are not recommended for use outside of a clinical trial.

The findings from these tests should not impact a woman’s decision to take a risk-reducing drug, have risk-reducing surgery or join a clinical trial for risk reduction. They also should not be used to assess risk for breast cancer screening recommendations.

More research is needed to learn how to use the findings from these tests.

Breast cancer risk assessment is not breast cancer screening

Tests such as ductal lavage, nipple aspiration and RPFNA are under study for risk assessment. Keep in mind, risk assessment is not breast cancer screening (tests used to find cancer early).

The U.S. Food and Drug Administration (FDA) states tests such as nipple aspiration are not substitutes for mammograms and should not be used in breast cancer screening or diagnosis [415].

 

Our commitment to research

At Susan G. Komen®, we are committed to ending deaths from breast cancer. Our Research Program is an essential driving force for achieving this mission.

Since our inception in 1982, Komen has provided funding to support research grants that have greatly expanded our knowledge of breast cancer and helped us understand that breast cancer is not just a single disease but many diseases, unique to each individual.

To date, Komen has provided more than $1.1 billion to researchers in 47 states, the District of Columbia, Puerto Rico and 23 countries to support research that has resulted in:

  • A better understanding of breast cancer, including earlier detection
  • Personalized, less invasive treatments for what was once a “one-treatment-fits-all” disease
  • Improvements in both quality of life and survival rates

Learn more about our continuing investment in research and the exciting research that we are funding, because nothing would make us happier than ending breast cancer forever.

 Updated 11/10/26

This content is regularly reviewed by an expert panel including researchers, practicing clinicians and patient advocates.

TOOLS & RESOURCES

PDF

Fact Sheet